Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Annie P Im
University of Pittsburgh Cancer Institute LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uci Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
- Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
- University of Cincinnati Cancer Center-Uc Medical Center
Cincinnati, Ohio, United States
- Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Dec 2024
- Primary completion
- 16 Sept 2027
- Completion
- 16 Sept 2027
- Last update posted
- 25 Aug 2026
- Registered enrollment
- 45
- Registry id
- NCT06514261
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.